Jun 23, 2021 — 3 min read
Two South Korean radiologists share benefits and feedback of using AI products for chest x-rays and mammograms in an actual patient care
Company expects to deliver the diagnostic value of AI and expand its implementation across clinical sites in the Asia-Pacific region
Lunit, a leading medical AI company, today announced the clinical application of its AI solution for chest radiography and mammography to be presented at this year’s Asian Oceanian Congress of Radiology(AOCR). The event will be fully virtual due to the COVID-19 pandemic, going live online, July 1-4, 2021.
Marking its 19th anniversary, AOCR aims to promote scientific collaborations, build professional rapport, and exchange knowledge amongst the Asian and Oceanian medical experts. Radiologists and pharma/medical device companies from more than 38 countries join to share the latest topics of medical imaging. It is known as one of the largest radiology conferences in the Asia-Pacific region, sponsored this year by global pharmaceutical and medical device companies such as Bayer, Guerbet, and Fujifilm.
Lunit will be participating in two symposiums featuring the benefits of AI solutions to analyze chest radiography(Lunit INSIGHT CXR) and mammography(Lunit INSIGHT MMG). The session will be hosted by the South Korean radiologists who are currently using the product in actual clinical setting. They will discuss how the AI solutions are implemented in their workflow and share feedback from hands-on experience.
On the first day of the conference, Dr. Chang-Min Park from Seoul National University Hospital will host a lunch symposium on “AI For Chest Radiographs: From Development To Clinical Implementation”. Dr. Eun-Kyung Kim from Yongin Severance Hospital will present on ‘Application of AI for Mammography’ during the breakfast symposium on July 4th.
“We are glad to have this opportunity to share our AI solutions at AOCR, one of the largest conferences in the Asia-Pacific region. Lunit has participated in multiple conferences globally, but the fact that actual users of our product are sharing their experience and insights is especially meaningful,” said Brandon Suh, CEO of Lunit. “We hope participants of the sessions will leave with new insights for AI, hopefully leading to an expansion of the implementation of Lunit AI among clinical sites in the Asia-Pacific region.”
Lunit INSIGHT products are now being used in more than 270 medical institutions across 30 countries, supporting medical professionals to more accurately diagnose cancer through AI. With the recent implementations in general hospitals and healthcare institutions in Thailand, Indonesia, and Singapore, the company is accelerating its expansion in the Asia-Pacific market. It is CE marked and approved for commercial sales in around 35 countries including Australia, New Zealand, Singapore, Thailand, Malaysia, and more.
For more information about AOCR 2021, visit the official website here: https://aocr2021.com
Lunit wins Tumor Proliferation Assessment Challenge (TUPAC) 2016
Lunit to unveil data-driven imaging biomarker at RSNA 2016
Lunit to showcase AI-powered products at USCAP 2017
Lunit INSIGHT: The First-ever, Real-time Imaging AI Analytics on the Web
Cognitive biases and augmented intelligence in radiology
Uncertainty and Deep Learning
Lunit Returns to RSNA with Real-time Imaging Platform, Featuring Cloud-based A
Lunit Unveils “Lunit INSIGHT,” A New Real-time Imaging AI Platform on the Web at RSNA 2017
Lunit INSIGHT: Q&A with Brandon B. Suh, Chief Medical Officer at Lunit
Media Advisory: Lunit at RSNA 2018
Lunit Opens “Lunit INSIGHT for Mammography” for Public Access
Lunit Brings its Newest AI Solution for Mammography to RSNA 2018
Lunit Partners with Fujifilm and Salud Digna to Provide Medical AI Solution in Mexico
Lunit announces new members in its advisory board: Dr. Eliot Siegel, Dr. Linda Moy, and Dr. Khan Siddiqui
Lunit to Introduce Medical AI Solutions at GTC 2019
Lunit to Present Abstracts on AI-powered Precision Pathology at 2019 AACR Annual Meeting
Lunit to Showcase AI Solution for Breast Cancer at SBI 2019
Lunit to Present Findings on the Predictive Power of AI Biomarker for Lung Cancer Immunotherapy at ASCO 2019
Lunit Receives Korea MFDS Approval for its AI Solution for Breast Cancer, Lunit INSIGHT MMG
Lunit Gets Korea MFDS Approval for its AI Solution for Chest X-ray, Lunit INSIGHT CXR 2
Lunit at RSNA 2019
Lunit Announces its First CE Mark for AI-Powered Chest X-ray Analysis Software, Lunit INSIGHT CXR
Lunit AI software clinically installed in global sites—to be presented at RSNA 2019
AI-assisted Radiologists Can Detect More Breast Cancer with Reduced False-positive Recall
Lunit Releases Its AI Online to Support Healthcare Professionals Manage COVID-19
Lunit to Present Findings on the Predictive Power of AI-based Analysis of Immune Phenotype at ASCO 2020
Lunit INSIGHT MMG, an AI Solution for Breast Cancer Detection, Now CE Certified
AI Solution for COVID-19, Developed by Medical AI Firm Lunit, Now Has Users in More Than 10 Countries
Lunit at ECR 2020: Providing Virtual Exhibition and Online Presentations
Emergent Connect Partners with Lunit to Provide Cloud Based AI Solutions
AI Analysis Can Improve Lung Cancer Detection on Chest Radiographs
AI has Added Value in Insurance Underwriting Process, Recent Pilot Project Between Lunit and Cathay Financial Innovation Lab Reveals
RSNA 2020--Lunit Collaborates with Global Giants in Presenting its AI Solution at Virtual Booths of GE Healthcare, FujiFilm, and Sectra
AI Proves Its Value in Assistance for Emergency Cases-- With Higher Accuracy and Timely Reporting Time of Chest Radiographs
Lunit Expands Collaboration with GE Healthcare to Advance AI Adoption across Healthcare Industry
AI Can Offer Fast and Reliable Examination to Triage COVID-19 Patients-- A Multicenter Retrospective Study Reveals
Recent Studies Reveal High Performance of Lunit AI in Breast Cancer Detection
South Korean Medical AI Provider and PACS Leader Enters Indonesian Market, to Help COVID-19 Screening and Diagnosis
What do medical studies say about AI for COVID-19 management?
What do the medical journals say about AI-powered mammography?
Research Using Lunit Demo Website
Lunit Presents AI-powered Pathologic Classification of Immune Phenotype that Predicts Response to Immunotherapy at USCAP 2021
What do the medical journals say about AI-powered chest x-ray interpretation?
Join our webinar with Dr. Fredrik Strand
From retrospective to prospective trials of AI in breast cancer screening
AACR 2021 - Lunit Presents Abstracts Demonstrating the Potential of its AI Biomarker in Cancer Treatment
Will AI Identify Breast Cancer Better Than Radiologists in Actual Clinical Screening?
Case of the Month | Where Is Breast Cancer?
AI-based Analysis of Cancer Tissue Predicts Response to Immunotherapy--Findings to Be Presented at ASCO 2021
Lunit Secures $26M Investment from Guardant Health in a Strategic Funding Round
A Multi-reader Study Finds Unnecessary CT Exams Can Be Reduced by 30% When Analyzing Chest Radiographs with AI
Fujifilm Introduces its AI-powered Product for Chest X-ray in Japan, in Collaboration with Lunit
Lunit Collaborates with Intel to Provide AI Solutions to CPU-Based Customers in Need of Effective X-ray Diagnosis
Lunit AI Applied to Clinical Trial for Drug Development for the First Time--Findings Presented at ESMO 2021